|
|
|||||||||
Clinical Investigations |
1 Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
2 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
3 Department of Nuclear Medicine, Wonkwang University, College of Medicine, Iksan, Korea
4 Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea
The aim of this study was to evaluate the diagnostic value of whole-body 18F-FDG PET imaging in the differentiation of metastatic brain tumor from primary brain tumor and in the localization of the primary lesion in patients with metastatic brain tumor. Methods: The subjects consisted of 127 patients (77 men, 50 women; mean age ± SD, 55 ± 12 y) with brain masses that were suspected to be metastatic brain tumors on radiologic studies: 77 with confirmed metastatic brain tumor and 50 with primary brain tumor. Whole-body 18F-FDG PET was performed on all patients. When the abnormal lesion was detected outside the brain, we interpreted the brain lesion as metastatic brain tumor. Results: In 61 of the 77 patients with metastatic brain tumor, primary lesions were detected using whole-body 18F-FDG PET. Of the remaining 16 patients (all false-negative cases), 7 were classified as metastases of unknown origin. In 47 of the 50 patients with primary brain tumor, whole-body 18F-FDG PET did not show any other abnormal lesions. The sensitivity, specificity, positive and negative predictive values, and accuracy of PET for the detection of primary origin were 79.2%, 94.0%, 95.3%, 74.6%, and 85.0%, respectively. The most common primary origin of metastatic brain tumors on PET examination was lung cancer (48/61, 78.7%). The concordance rate between 18F-FDG PET and conventional radiologic work-up was 80% in identifying primary lesion. Unknown bone or bone marrow metastases and unsuspected distant metastases were found in 14 patients (18%) and 24 patients (31%), respectively, on PET examination. Conclusion: Screening the patients with suspected metastatic brain tumors using whole-body 18F-FDG PET could be helpful in differentiating metastatic brain tumor from primary brain tumor and in detecting the primary lesion.
Key Words: whole-body PET FDG metastatic brain tumor
This article has been cited by other articles:
![]() |
N. Kosaka, T. Tsuchida, H. Uematsu, H. Kimura, H. Okazawa, and H. Itoh 18F-FDG PET of Common Enhancing Malignant Brain Tumors Am. J. Roentgenol., June 1, 2008; 190(6): W365 - W369. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Posther, L. M. McCall, D. H. Harpole Jr., C. E. Reed, J. B. Putnam Jr., V. W. Rusch, and B. A. Siegel Yield of Brain 18F-FDG PET in Evaluating Patients with Potentially Operable Non-Small Cell Lung Cancer J. Nucl. Med., October 1, 2006; 47(10): 1607 - 1611. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Vesselle, E. Turcotte, L. Wiens, and D. Haynor Application of a Neural Network to Improve Nodal Staging Accuracy with 18F-FDG PET in Non-Small Cell Lung Cancer J. Nucl. Med., December 1, 2003; 44(12): 1918 - 1926. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |